ADC Therapeutics Slumps on Cancer Drug Safety Scare

ADC Therapeutics slumps on cancer drug safety scare

Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.

An ADC specialist sinks on safety concerns for blood cancer drug

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”

ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm - European Biotechnology Magazine

Swiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events in the experimental arm has overshadowed the efficacy readout and triggered a sharp investor backlash. The post ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm appeared first on European B…

ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates

ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...